Uroplasty (UPI) Reports a Q3 Loss
More News related to UPI
- Uroplasty Reports Results for Second Quarter FY2010
- Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
- Unusual 11 Mid-Day Movers 10/14: CHIO, ACPW, JADE, CNO Higher; CXM, HILL, UCBH, UPI Lower
- Morning Movers 10/14: ACPW, CNO, ZIOP, CHIO, JADE Higher; UPI, UCBH Lower
- Uroplasty (UPI) Won't Comment On Unusual Stock Activity
More News related to Earnings
- Communications Systems (JCS) Reports Year-Over-Year Decline in Q3 Earnings
- Communications Systems (JCS) Posts Q3 EPS of $0.22, Down Y/Y
- Atmos Energy (ATO) Posts Q4 Loss of $0.17, Wider than Estimates
- China Digital TV (STV) Misses Q3 EPS by 2c; Guides Below for Q4
- Ralcorp (RAH) Misses Street's Q4 Views; Announces 7M Share Buyback
Uroplasty, Inc. (Amex: UPI) reports a Q3 loss of $0.07 compared to a net loss for the same quarter in the prior year of $0.10 per diluted share. UPI reported record sales of $2.2 million for the third quarter of fiscal 2007 ended December 31, 2006, up 36%, or $566,000, from $1.6 million for the same quarter in the prior year.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions, including urinary and fecal incontinence, overactive bladder and vesicoureteral reflux.
Related Categories
EarningsStocks Mentioned
+0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
